Triple X syndrome is also known as triplo-X, trisomy X, XXX syndrome, 47,XXX aneuploidy. It is a form of chromosomal variation characterized by the presence of an extra X chromosome.
Triple-X syndrome is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). Approximately 0.10% or 1 per 1,000 newborn girls suffer from triple X syndrome.
Treatment for this disorder is targeted for physical therapy, between 12 and 15 months for speech delay, prior to first grade for early signs of reading dysfunction and by third grade for anxiety and ADHD.
Most of the research that has been published on Triple X Syndrome focuses on case studies and medical/physiological data on patients with Triple X Syndrome.